Article
Oncology
Mohammad Alyami, Pierre-Emmanuel Bonnot, Frederic Mercier, Nathalie Laplace, Laurent Villeneuve, Guillaume Passot, Naoual Bakrin, Vahan Kepenekian, Olivier Glehen
Summary: The study showed that PIPAC with low-dose cisplatin and doxorubicin in combination with systemic chemotherapy is safe and feasible for patients with unresectable PM from gastric origin. The survival data are encouraging and support further clinical studies in this indication.
Article
Oncology
Julia Kleber, Jordi Yang Zhou, Florian Weber, Florian Bitterer, Patricia Hauer, Paul Kupke, Katharina Kronenberg, Edward K. Geissler, Hans J. Schlitt, Matthias Hornung, James A. Hutchinson, Jens M. Werner
Summary: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment option for peritoneal carcinomatosis (PC) from colorectal cancer (CRC). However, survival outcomes are only marginally superior to other treatments. This study investigates the immune phenotype of T cells in patients with PC.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
David N. Hanna, Rebekah Macfie, Muhammad O. Ghani, Andrew Hermina, Alexander Mina, Da Eun Cha, Christina E. Bailey, Noah Cohen, Daniel Labow, Benjamin Golas, Umut Sarpel, Deepa Magge, Kamran Idrees
Summary: The study aimed to evaluate the oncologic outcomes of two popular systemic chemotherapy approaches for patients with colorectal peritoneal metastases. The findings showed that the total neoadjuvant therapy approach was associated with improved recurrence-free survival, but there was no significant difference in overall survival compared to the sandwich chemotherapy approach.
JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Annamaria Agnes, Alberto Biondi, Roberto Persiani, Antonio Laurino, Rossella Reddavid, Maurizio De Giuli, Federico Sicoli, Ferdinando Cananzi, Stefano De Pascale, Uberto Fumagalli, Federica Galli, Stefano Rausei, Laura Lorenzon, Domenico D'Ugo
Summary: Two risk models (PERI-Gastric 1 and 2) were developed to assess the risk of peritoneal recurrence after curative-aim gastrectomy, based on multivariable logistic regression results and discrimination evaluation using the area under the receiver operating curve. These models could guide the use of prophylactic treatments.
Article
Oncology
Praveen D. Chatani, Alexander Manzella, Yelizaveta Y. Gribkova, Brett L. Ecker, Toni Beninato, Timothy Kennedy, Henry A. Pitt, Henry Richard Alexander
Summary: No association was found between hospital volume for CRS/HIPEC and post-operative outcomes. These data suggest that in academic medical centers with HIPEC programs, outcomes for commonly treated cancers are not associated with hospital volume.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Nutrition & Dietetics
Alba Fernandez-Candela, Alicia Calero, Luis Sanchez-Guillen, Javier Escrig-Sos, Jose A. Barreras, Francisco Lopez-Rodriguez-Arias, Laura Armananzas, Ana Murcia, Antonio Arroyo, Francisco Javier Lacueva
Summary: The study assessed the impact of preoperative immunonutrition intake on postoperative major complications in patients undergoing cytoreductive surgery, showing that immunonutrition intake was associated with a decreased risk of postoperative complications.
Article
Oncology
Christopher W. Mangieri, Omeed Moaven, Cristian D. Valenzuela, Richard A. Erali, Konstantinos Votanopoulos, Perry Shen, Edward A. Levine
Summary: This is the largest study to evaluate the relationship between high-grade appendiceal neoplasms and CRS-HIPEC and NAT. The study found that NAT had no impact on disease burden, cytoreduction, or recurrence patterns, but it was associated with decreased overall survival and disease-free survival.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Aditi Bhatt, Pascal Rousset, Nazim Benzerdjeb, Praveen Kammar, Sanket Mehta, Loma Parikh, Gaurav Goswami, Sakina Shaikh, Vahan Kepenekian, Guillaume Passot, Olivier Glehen
Summary: The study found that the surgical Peritoneal Cancer Index (sPCI) and radiologic Peritoneal Cancer Index (rPCI) were not accurate predictors of pathologic complete response (pCR) after cytoreductive surgery for colorectal peritoneal metastases. Patients with an sPCI of 3 or lower had an 80% probability of experiencing pCR. The impact of KRAS gene mutations on pCR should be further evaluated.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Surgery
Daniel Solomon, Natasha Leigh, Eliahu Bekhor, Yael Feferman, Poojaben Dhorajiya, Daniela Feingold, Margaret Hofstedt, Samantha N. Aycart, Benjamin J. Golas, Umut Sarpel, Daniel M. Labow, Deepa R. Magge
Summary: This study retrospectively reviewed patients with peritoneal metastases of colorectal cancer who underwent CRS/HIPEC and found that mBRAF mutation was independently associated with earlier recurrence, leading to poor median DFS. Strict patient selection is advisable for these patients.
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND
(2021)
Article
Oncology
Yusuf Ciftci, Shannon N. Radomski, Fabian M. Johnston, Jonathan B. Greer
Summary: This study aimed to determine the risk of financial toxicity for patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), and found that high out-of-pocket expenditures and lower income quartiles are risk factors for financial toxicity.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Medicine, General & Internal
Megan M. Harper, Joseph Kim, Prakash K. Pandalai
Summary: Peritoneal carcinomatosis is a poor prognostic factor for all malignancies and systemic therapies have limited efficacy. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are surgical interventions that have improved outcomes, but long-term survival remains rare and recurrence is common. Therefore, the development of novel therapeutics and techniques is necessary to improve outcomes.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Surgery
Victor P. Gazivoda, Aaron W. Kangas-Dick, Alissa A. Greenbaum, Joshua Roshal, Chunxia Chen, Dirk F. Moore, Russell C. Langan, Timothy J. Kennedy, Christine Minerowicz, H. Richard Alexander
Summary: This study aimed to characterize the frequency of PD-L1 expression and the role of immunotherapy in malignant peritoneal mesothelioma (MPM). The results showed a high frequency of PD-L1 expression in MPM patients, which may be associated with more aggressive tumor biology. These findings are important for further evaluation of checkpoint inhibition in MPM patients.
JOURNAL OF SURGICAL RESEARCH
(2022)
Review
Oncology
David J. J. Byrwa, Clare J. J. Twist, Joseph Skitzki, Elizabeth Repasky, P. Ben Ham, Ajay Gupta
Summary: Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment method that targets microscopic peritoneal disease. This review focuses on HIPEC in pediatrics, discussing chemotherapy choice, post-operative morbidity and mortality, and impact on overall survival. Although HIPEC with cisplatin is generally well-tolerated with minimal complications, its effect on survival compared to systemic chemotherapy and debulking surgery is uncertain.
Article
Gastroenterology & Hepatology
Mary Garland-Kledzik, Abhineet Uppal, Yalda B. Naeini, Stacey Stern, Richard Erali, Anthony J. Scholer, Adam M. Khader, Juan A. Santamaria-Barria, Kathleen Cummins-Perry, Yi Zhou, Konstantinos Votanopoulos, Perry Shen, Edward A. Levine, Anton J. Bilchik
Summary: This study evaluated the immune profiles of patients with colorectal peritoneal carcinomatosis and their correlation with overall survival. The increased CD3/CD4 IM ratio was associated with improved overall survival, suggesting potential implications for patient selection and novel pathways for effective immunotherapy.
JOURNAL OF GASTROINTESTINAL SURGERY
(2021)
Article
Oncology
Bjorg Jonsdottir, Marta Lomnytska, Inger Sundstrom Poromaa, Ilvars Silins, Karin Stalberg
Summary: The study found PCI to be an excellent predictor of incomplete CRS, suggesting consideration of neoadjuvant chemotherapy if the PCI is higher. The reason for open-close surgery was mainly massive carcinomatosis on the small bowel.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Oncology
Andreas Domen, Carl VAN Paesschen, Karen Zwaenepoel, Suzan Lambin, Patrick Pauwels, Marika Rasschaert, E. V. A. Segelov, Marc Peeters, Hans Prenen
Summary: MEK inhibition with cobimetinib has shown significant effectiveness in the treatment of STMC harboring an AGK-BRAF fusion. This case report highlights the importance of next generation sequencing in guiding personalized therapy.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Marwan G. Fakih, Scott Kopetz, Yasutoshi Kuboki, Tae Won Kim, Pamela N. Munster, John C. Krauss, Gerald S. Falchook, Sae-Won Han, Volker Heinemann, Kei Muro, John H. Strickler, David S. Hong, Crystal S. Denlinger, Gustavo Girotto, Myung-Ah Lee, Haby Henary, Qui Tran, Joseph K. Park, Gataree Ngarmchamnanrith, Hans Prenen, Timothy J. Price
Summary: Sotorasib, a specific inhibitor of KRAS(G12C) protein, showed modest anti-tumour activity and manageable safety in heavily pretreated patients with colorectal cancer in a phase 2 trial. The overall response rate of 9.7% did not reach the benchmark, but sotorasib is being evaluated in combination with other therapeutics to enhance potential activity and address potential resistance mechanisms.
Article
Gastroenterology & Hepatology
Julia Schroeder, Laura Chegwidden, Carlo Maj, Jan Gehlen, Jan Speller, Anne C. Boehmer, Oleg Borisov, Timo Hess, Nicole Kreuser, Marino Venerito, Hakan Alakus, Andrea May, Christian Gerges, Thomas Schmidt, Rene Thieme, Dominik Heider, Axel M. Hillmer, Julian Reingruber, Orestis Lyros, Arne Dietrich, Albrecht Hoffmeister, Matthias Mehdorn, Florian Lordick, Gertraud Stocker, Michael Hohaus, Daniel Reim, Jennis Kandler, Michaela Mueller, Alanna Ebigbo, Claudia Fuchs, Christiane J. Bruns, Arnulf H. Holscher, Hauke Lang, Peter P. Grimminger, Dani Dakkak, Yogesh Vashist, Sandra May, Siegfried Gorg, Andre Franke, David Ellinghaus, Sara Galavotti, Lothar Veits, Josef Weismuller, Jens Dommermuth, Udo Benner, Thomas Roesch, Helmut Messmann, Brigitte Schumacher, Horst Neuhaus, Carsten Schmidt, Thaddaus T. Wissinowski, Markus M. Noethen, Jing Dong, Jue-Sheng Ong, Matthew F. Buas, Aaron P. Thrift, Thomas L. Vaughan, Ian Tomlinson, David C. Whiteman, Rebecca Claire Fitzgerald, Janusz Jankowski, Michael Vieth, Andreas Mayr, Puya Gharahkhani, Stuart MacGregor, Ines Gockel, Claire Palles, Johannes Schumacher
Summary: This study utilized GWAS, genetic correlation analysis, and polygenic risk modeling to investigate the genetic causes of BE/EA. The findings identified new risk loci and candidate genes associated with BE/EA development. The study also revealed differences in the etiology of BE and EA and demonstrated improved risk prediction models when combining PRS with risk factors. These findings provide valuable insights into the mechanisms underlying BE/EA and improve our understanding of the disease.
Article
Oncology
Yana Debie, Jonas R. M. Van Audenaerde, Timon Vandamme, Lieselot Croes, Laure-Anne Teuwen, Lise Verbruggen, Greetje Vanhoutte, Elly Marcq, Lisa Verheggen, Debbie Le Blon, Bart Peeters, Maria E. Goossens, Pieter Pannus, Kevin K. Arien, Sebastien Anguille, Annelies Janssens, Hans Prenen, Evelien L. J. Smits, Christof Vulsteke, Eva Lion, Marc Peeters, Peter A. van Dam
Summary: Patients with cancer have reduced humoral responses after double-dose COVID-19 vaccination, but their cellular response is comparable to healthy individuals. A third dose of BNT162b2 can boost immune responses in both healthy people and cancer patients. This study compares the effects of a third dose of BNT162b2 after homologous (double-dose BNT162b2) and heterologous (ChAdOx1) vaccination in cancer patients.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Andreas Domen, Christophe Deben, Jasper Verswyvel, Tal Flieswasser, Hans Prenen, Marc Peeters, Filip Lardon, An Wouters
Summary: Cellular senescence is a mechanism in which cells enter a state of stable cell-cycle arrest with secretory features in response to cellular stress. It has been historically seen as a protective mechanism against cancer by eliminating damaged cells. However, the accumulation of senescent cells can have long-term detrimental effects and contribute to age-related diseases, including cancer. The role of cellular senescence in cancer is ambiguous and controversial, and its detection and study in cancer patients present challenges. This review highlights the methods and challenges of detecting cellular senescence in cancer patients, and discusses its prognostic implications.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Maxim Le Compte, Edgar Cardenas De La Hoz, Sofia Peeters, Evelien Smits, Filip Lardon, Geert Roeyen, Steve Vanlanduit, Hans Prenen, Marc Peeters, Abraham Lin, Christophe Deben
Summary: This paper presents a semi-automated methodology for seeding, treating, and imaging PDTOs in a high-throughput, 384-well format. It also introduces viability marker-free image analysis software to quantify growth rate-based drug response metrics and improve reproducibility. The method allows for improved classification of cytotoxic and cytostatic drug responses and quantification of drug-response heterogeneity.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
(2022)
Review
Oncology
Sofie Seghers, Laure-Anne Teuwen, Michiel Beyens, Dennis De Blick, Vito Sabato, Didier G. Ebo, Hans Prenen
Summary: Immediate hypersensitivity reactions (IHRs) to antineoplastic agents are common and can significantly impact the treatment of cancer patients. However, clear guidelines for diagnosis and management are lacking, especially from an oncologic perspective. This review focuses on defining IHRs and discussing their underlying mechanisms, summarizing the epidemiology of common causative agents, and providing guidance on diagnosis and treatment to improve the care of cancer patients.
CANCER TREATMENT REVIEWS
(2023)
Review
Oncology
Hans Dedecker, Laure-Anne Teuwen, Timon Vandamme, Andreas Domen, Hans Prenen
Summary: Upper gastrointestinal tract tumors have historically had a poor prognosis. Multidisciplinary discussion is necessary when deciding on the treatment approach for esophageal or gastric cancers, which may include surgery, radiotherapy, systemic therapy, or a combination of these modalities. Immunotherapy, particularly targeting immune checkpoint proteins such as PD-1/PD-L1, has shown promising results in improving overall survival for advanced, metastatic, or recurrent esophageal and gastric cancer, regardless of specific molecular characteristics like PD-L1 expression level or microsatellite instability. This review provides an overview of the recent advances in immunotherapy treatment for esophageal and gastric cancer.
CLINICAL COLORECTAL CANCER
(2023)
Review
Oncology
Katleen Janssens, Chinouk Lambrechts, Barbara Geerinckx, Ken Op de Beeck, Guy Van Camp, Helena Oliveres, Hans Prenen, Timon Vandamme, Marc Peeters
Summary: One of the major challenges in digestive oncology is selecting the optimal therapy for RAS-mutated metastatic colorectal cancer (mCRC). Recent developments in targeting the RAS-pathway have shown promising results and may lead to clinical benefits for patients in the coming years. Although resistance remains a concern, strategic combination regimens have been developed to overcome this issue. In this review, we summarize the standard of care and discuss emerging therapies for RAS-mutated mCRC.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Oncology
Katleen Janssens, Erik Fransen, Guy Van Camp, Hans Prenen, Ken Op de Beeck, Nancy Van Damme, Marc Peeters
Summary: This study provides evidence that left-sided colorectal cancer has a significantly better prognosis compared to right-sided colorectal cancer, in all stages and ages combined. The survival of left-sided colorectal cancer is also longer than right-sided colorectal cancer in stage IV, regardless of MMR, RAS, and BRAF status.
Article
Oncology
Melinda A. Pruis, Matthew G. Krebs, Ruth Plummer, Filip De Vos, Eric Angevin, Hans Prenen, Martin D. Forster, Glen Clack, Annegret van der Aa, Marc Tjwa, Ellen Jansen, Timothy Perera, Martijn P. Lolkema
Summary: Targeted therapy has improved outcomes in non-small cell lung cancer (NSCLC) patients with mesenchymal epithelial transition (MET) exon 14 skipping mutations (METex14) and MET amplifications. This study aimed to determine the safety and recommended phase II dose of OMO-1 and assess preliminary clinical efficacy in METex14-positive NSCLC and other MET-positive solid tumors.
Article
Multidisciplinary Sciences
Carla Riera-Domingo, Eduarda Leite-Gomes, Iris Charatsidou, Peihua Zhao, Giovanna Carra, Federica Cappellesso, Larissa Mourao, Maxim De Schepper, Dana Liu, Jens Serneels, Mohamad-Gabriel Alameh, Vladimir V. Shuvaev, Tatjana Geukens, Edoardo Isnaldi, Hans Prenen, Drew Weissman, Vladimir R. Muzykantov, Stefaan Soenen, Christine Desmedt, Colinda L. G. J. Scheele, Anna Sablina, Mario Di Matteo, Rosa Martin-Perez, Massimiliano Mazzone
Summary: In the premetastatic niche, endothelial cells express tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its cognate death receptor 5 (DR5). TRAIL interacts with DR5 intracellularly to prevent its signaling and maintain a quiescent vascular phenotype. Absence of endothelial TRAIL leads to DR5 activation, causing endothelial cell death and compromising vascular integrity, thereby promoting cancer cell metastasis.
Article
Medicine, General & Internal
Laure-Anne Teuwen, Evelyne Roets, Pieter D'Hoore, Patrick Pauwels, Hans Prenen
Summary: This study aimed to assess the application of next-generation sequencing (NGS) in detecting tumor-specific genomic alterations and initiating matched targeted treatment for advanced cancer patients. The analysis of solid tumor biopsies from 464 patients using the Foundation Medicine assay revealed common altered genes and high tumor mutational burden. Out of the patients with actionable targets, a significant proportion received matched treatment, including participation in clinical trials.
Article
Chemistry, Medicinal
Danielle Delombaerde, Johan De Sutter, Lieselot Croes, Delphine Vervloet, Veronique Moerman, Nico van de Veire, Anne-Marie Willems, Kristien Wouters, Marc Peeters, Hans Prenen, Christof Vulsteke
Summary: The lack of solid data and prospective studies has resulted in a lack of clear guidelines for cardiovascular monitoring in patients receiving immune checkpoint inhibitors (ICIs). In order to address this issue, we have initiated the CAVACI trial to investigate the short- and long-term cardiovascular effects of ICIs. Patient recruitment started in January 2022.
Article
Oncology
Katleen Janssens, Erik Fransen, Guy Van Camp, Hans Prenen, Ken Op de Beeck, Nancy Van Damme, Marc Peeters
Summary: This study confirms that left-sided colorectal cancer has a better prognosis compared to right-sided colorectal cancer in the Belgian population. The presence of biomarkers such as MMR, BRAF, and RAS status does not significantly affect the prognostic effect of primary tumor location.
